STAT+: Kyverna’s cell therapy shows lasting autoimmune benefit

Data ReadoutpositivePositive

AI Analysis

Summary

Kyverna Therapeutics announced positive clinical data for its cell therapy in autoimmune disease, with patients demonstrating durable benefit and remaining off other therapies. The company is advancing toward potential commercialization as a first-in-class cell therapy for autoimmune indications.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Many patients remained off other therapies, showing lasting autoimmune benefit

Importance:7/10

Sentiment:

0.75

cell therapyautoimmune diseaseclinical dataKyverna Therapeutics

Related Companies

$TRAX

Read the original article

Published by STAT News on September 24, 2026 1:52 PM

Read Original